Pulmotype provides pathologists with a valuable new tool to help their oncologist clients understand which patients are eligible for a number of new therapies now available for the treatment of NSCLC . Its ability to accurately sub-classify lung cancer will enable physicians to make much more informed and effective therapy decisions.